Individuals susceptible to SARS-CoV-2 and the illness it causes (COVID-19) are comprisedof heterogeneous populations with a large risk spectrum for more severe disease.Pre-existing risk factors for a more severe course include respiratory and cardiovasculardisease, morbid obesity, diabetes, underlying kidney or liver disease, andimmunocompromised status. Whether children and young adults with inflammatory boweldisease (IBD) or juvenile idiopathic arthritis (JIA) receiving immunomodulating biologicand other therapies which are known to increase risk of viral infection are at increasedrisk of complications from COVID-19 or post-infectious co-morbidities, including therecently described multi inflammatory syndrome (MISC), is entirely unclear. This researchfocuses on the heretofore uncharacterized immune response to SARS-CoV-2 infection inchildren and young adults with IBD or JIA who are receiving maintenance immunosuppressivebiologic therapies. Given the large Connecticut based infusion program, in a region ofthe United States with a recent large outbreak of COVID-19, the investigators have aunique opportunity to address a glaring knowledge gap in this unique pediatric,adolescent, and young adult population. The investigators will longitudinally determineantibody development and durability to SARS-CoV-2 in approximately 450-500 children andyoung adults with IBD or JIA receiving biologic therapy using a highly sensitive andspecific quantitative assay utilizing novel technology. This period will include a returnto school or work for many with likely resurgent infections, as well as the possibleintroduction of anti-SARS CoV-2 vaccines. The specific aim is to study the acute andconvalescent antibody responses to SARS-CoV-2 infection in a cohort of children and youngadults receiving infusions of biologic therapies for IBD and JIA.